[RVTY] Revvity Thesis 2026: Post-Split Reset Tests Biotech Funding Cycle Recovery

Key Takeaways

• FY2025 revenue ~$2.7-2.9B (+1-3% YoY) with adj. EPS ~$4.70-4.90 — Revvity Inc. is a life sciences + diagnostics company formed via 2023 PerkinElmer split into Revvity (life sciences + diagnostics focus) + PerkinElmer Inc. (selected analytical instruments retained legacy PerkinElmer brand). FY2025 reflects continued biotech funding cycle pressure (post-2021 boom selected funding compression continuing FY2024-2025) + selected China weakness + selected operational reset under continued CEO Prahlad Singh + selected diagnostics segment stability.
• 2 segments: Life Sciences ~62% + Diagnostics ~38% — Life Sciences includes selected research instruments + reagents + selected reagents + selected (selected biotech R&D customer base sensitive to biotech funding cycle); Diagnostics includes newborn screening (selected market leadership) + selected reproductive health + selected immunoassay + selected (more stable cycle profile).
• CEO Prahlad Singh since 2020 — Singh continued post-split as Revvity CEO (PerkinElmer pre-split CEO since 2020). Singh background: ex-Roper Technologies + selected industrial executive; ~25-year career. Singh's tenure has executed: 2023 PerkinElmer split (separated PerkinElmer Inc. analytical instruments + Revvity life sciences/diagnostics) + selected operational reset + selected biotech funding cycle navigation. Capital return: dividend $0.28-0.32/share annual + buybacks $200-400M; net debt ~$3-4B; investment-grade Baa3/BBB- credit rating.
• FY2026 thesis: Post-split operational reset + biotech funding cycle recovery + diagnostics stability + capital return — Selected continued operational reset under Singh; selected biotech funding cycle recovery would drive Life Sciences instruments demand recovery; Diagnostics stability provides anchor; selected capital return discipline. Key risks: biotech funding cycle (selected continued biotech IPO + funding compression), China demand (selected continued Chinese pharma R&D capex weakness), post-split execution friction.

Company Background

Revvity Inc. (NYSE: RVTY), formed via May 2023 PerkinElmer Inc. split into Revvity (life sciences + diagnostics) + PerkinElmer Inc. (analytical instruments selected industrial laboratory; sold to New Mountain Capital January 2023 for $2.45B + selected post-split rebranding), is a life sciences + diagnostics company. Headquartered in Waltham, Massachusetts, Revvity operates serving selected biotech + pharma + clinical diagnostics + selected applied markets globally. Revvity's competitive moat rests on three structural advantages: (1) selected life sciences research instrument + reagent portfolio — selected research instruments + reagents + selected automation serving biotech + pharma R&D customers; (2) selected diagnostics niche leadership — selected newborn screening market leadership + selected reproductive health diagnostics; (3) selected post-split operational simplification — selected pure-play life sciences + diagnostics focus post-2023 split.

CEO Prahlad Singh continued post-split as Revvity CEO (PerkinElmer pre-split CEO since 2020). Singh's background:

• PerkinElmer CEO (2020-2023 pre-split)
• Roper Technologies + selected operational/M&A executive roles
• ~25-year industrial executive career

Singh's tenure has executed:

• 2020-2023 PerkinElmer Era: led PerkinElmer through COVID-19 testing demand surge + selected M&A (BioLegend acquisition 2021 ~$5.25B) + selected portfolio review
• January 2023 PerkinElmer Inc. Sale: $2.45B sale of analytical instruments business to New Mountain Capital (selected industrial laboratory analytical instruments retained PerkinElmer brand under New Mountain ownership; remaining business rebranded Revvity)
• May 2023 Revvity Rebrand: official rebrand of remaining PerkinElmer life sciences + diagnostics business as Revvity
• 2023-2025 Operational Reset: selected post-split operational discipline + selected biotech funding cycle navigation

Singh's strategic positioning emphasizes:

• Life Sciences research instrument + reagent scaling
• Diagnostics niche leadership (newborn screening + reproductive health)
• Selected operational excellence
• Selected M&A pipeline (selected smaller bolt-on)
• Capital return discipline

Business Structure

Revvity reports operations across 2 segments:

1. Life Sciences — ~$1.7-1.8B FY2025 (~62% of revenue):

• Research instruments (selected automation + selected imaging + selected)
• Reagents (BioLegend antibodies acquired 2021 + selected)
• Selected research applications (biotech + pharma + selected academic)
• Operating margin ~22-25%
• Selected biotech funding cycle exposure

2. Diagnostics — ~$1.0-1.1B FY2025 (~38% of revenue):

• Newborn screening (selected market leadership; selected critical screening for genetic disorders + selected congenital conditions)
• Reproductive health (selected prenatal + fertility + selected)
• Selected immunoassay + selected
• Operating margin ~25-30%
• More stable cycle profile

Key Core Metrics

Financial Performance Summary

Capital Return Framework (FY2025)

Market Evaluation

Revvity Inc. trades at ~24-28x forward earnings with ~0.4% dividend yield, reflecting life sciences + diagnostics post-split valuation framework where investors price near-term biotech funding + Diagnostics stability + capital return into multiple. Bull case: biotech funding cycle recovery + Life Sciences instrument demand recovery + Diagnostics stability + selected operational reset under Singh + selected capital return discipline; valuation reflects selected biotech concerns providing recovery upside. Bear case: biotech funding cycle (selected continued biotech IPO + funding compression), China demand (selected continued Chinese pharma R&D capex weakness), post-split execution friction.

Compared to peers: RVTY vs Thermo Fisher Scientific (TMO, larger life sciences + diagnostics ~$43B revenue); RVTY vs Danaher (DHR, larger life sciences + diagnostics ~$24B revenue); RVTY vs Agilent (A, similar life sciences instruments ~$6.5B); RVTY vs Bio-Rad Laboratories (BIO, similar size ~$2.5B + selected); RVTY vs Bruker (BRKR, smaller analytical ~$3B); RVTY vs Waters Corporation (WAT, analytical instruments ~$3B). Revvity's selected post-split focus + selected newborn screening leadership + BioLegend reagents create structural advantages but selected scale gap vs Thermo + Danaher.

Post-Split Reset + Biotech Recovery + Diagnostics

The FY2026 thesis for Revvity Inc. centers on post-split operational reset + biotech funding cycle recovery + Diagnostics stability + capital return discipline.

Post-Split Operational Reset:

• 2023 PerkinElmer Inc. split: analytical instruments sold to New Mountain Capital ($2.45B); remaining life sciences + diagnostics rebranded Revvity
• Selected pure-play focus simpler portfolio
• Post-split operational discipline + selected cost reduction
• FY2024-2025 progress: continued operational reset + selected operational excellence

Biotech Funding Cycle Recovery:

• FY2022-2024 biotech funding environment severely compressed (post-2021 boom downturn)
• Life Sciences segment cyclical (biotech R&D capex sensitivity)
• FY2024-2025 selected biotech recovery beginning (selected IPO activity reopening)
• FY2026 expected: continued selected biotech recovery driving Life Sciences instrument demand
• Long-term: biotech R&D continues structural growth

Diagnostics Stability:

• Diagnostics segment ~$1.0-1.1B more stable cycle profile
• Newborn screening selected market leadership (selected critical screening required for selected hospitals)
• Reproductive health + selected immunoassay
• Selected stable demand vs Life Sciences cyclical
• FY2025-2026 expected: continued Diagnostics stability + selected modest growth

China Weakness Status:

• ~10-15% revenue exposure to China
• Selected pharma anti-corruption + selected China R&D capex weakness
• FY2025-2026 expected: selected stabilization

Capital Return:

• Dividend $0.28-0.32/share FY2025 (modest growth)
• Buybacks $200-400M FY2025 (~1-2%/yr share count reduction)
• Total capital return $235-440M
• Net debt $3-4B
• Investment-grade Baa3/BBB-

FY2026 Outlook:

• Revenue toward $2.8-3.0B FY2026 (+3-5% on biotech recovery + Diagnostics stability)
• Adj. EPS toward $4.90-5.20 (+4-7%)
• Operating margin toward 26-28%
• FCF $550-650M
• Capital return $250-450M
• Dividend toward $0.30-0.34/share
• FY2027 outlook: revenue $3.0-3.2B, adj. EPS $5.20-5.50, capital return $300-500M

Key Risks:

• Biotech funding cycle (selected continued biotech IPO + funding environment compression affecting Life Sciences instrument demand)
• China demand (selected continued Chinese pharma R&D capex weakness; ~10-15% revenue exposure)
• Post-split execution friction (selected operational reset extending)
• Selected commodity input cost inflation
• Selected currency volatility (international ~50%)
• Selected competitive intensity from Thermo + Danaher + Agilent + selected
• Selected regulatory environment (selected newborn screening regulatory changes)
• Selected M&A integration (BioLegend continued integration)

FY2026 Watch Items:

• Life Sciences revenue trajectory (target +3-5%)
• Diagnostics revenue trajectory (target +3-5%)
• Adj. EPS growth (target +4-7%)
• Operating margin trajectory (target 26-28%)
• Dividend trajectory
• Capital return execution
• Biotech funding environment indicators
• Selected M&A announcements

Revvity Inc.'s FY2026 thesis is post-split operational reset + biotech funding cycle recovery + Diagnostics stability + capital return discipline. Validation: biotech recovery + Diagnostics stable + dividend continued + buybacks delivered = thesis intact. Failure mode: biotech funding compression severe + China weakness extends + post-split execution friction = life sciences + diagnostics cycle compression Revvity cannot fully insulate against despite selected newborn screening leadership + post-split focus advantages.